Safety and Efficacy of Two Year Spnol and Maximal R Blockad Therapy
Status:
Withdrawn
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
NephroNet proposes to examine whether combining Spironolactone with maximal RAAblockade will
further reduce urinary protein at one year and whether prolonged therapy 24 months) is able
to slow the decline in GFR. Because of combination MRand RAAS therapsignificantly increases
the risk for clinically significantcccc, the investigators also whether the addition of
Patironts facilitates the use of combination therapy and allows a larger proportion of
diabetic patients the potential benefit of combination therapy on renal function.